MarketCapExport financials
Blueprint Medicines Corporation (BPMC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Blueprint Medicines Corporation Income Statement 2024-2011 | BPMC
Brief overview of income trends at Blueprint Medicines Corporation
The figures are compared over a five-year interval. The revenue attributed to Blueprint Medicines Corporation moved from 66.5 million dollars to 509 million dollars between the two endpoints. Overall revenue changed by +665%, equal to an annualized rate of about 50.2%. This pace points to rapid expansion of the business.
EBITDA changed from −$356 million to $16.3 million (+104.6%). The operating result developed less favorably than sales. EBITDA margin moved from −535.3% to 3.2%. The increased EBITDA share is a positive sign.
The final result was −348 million dollars initially and −67.1 million dollars in the final year. The loss narrowed, although sustainable profitability has not yet returned.
The market value of the business moved from 3.1 billion dollars to 6 billion dollars, or +94%. The market broadly confirmed the positive direction of the business.
Overall conclusion
The figures do not all move in the same direction. The constructive conclusion rests on improving net profitability, sales growth and positive operating leverage. The most visible risks are a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
5.96 B | 5.31 B | 2.66 B | 6.27 B | 6.12 B | 3.07 B | 3.11 B | 3.06 B | 913 M | 287 M | - | - | - | - |
Shares |
62.9 M | 60.6 M | 59.6 M | 58.5 M | 54.5 M | 47.8 M | 43.9 M | 37.8 M | 27.5 M | 18.2 M | - | - | - | - |
Historical Prices |
94.8 | 87.6 | 44.5 | 107 | 112 | 80.1 | 53.9 | 75.4 | 28.1 | 26.3 | - | - | - | - |
Net Income |
-67.1 M | -507 M | -558 M | -644 M | 314 M | -348 M | -237 M | -148 M | -72.5 M | -52.8 M | -40.3 M | -20.9 M | - | - |
Revenue |
509 M | 249 M | 204 M | 180 M | 794 M | 66.5 M | 44.5 M | 21.4 M | 27.8 M | 11.4 M | - | - | - | - |
Cost of Revenue |
20.2 M | 8.54 M | 17.8 M | 17.9 M | 425 K | - | - | - | - | - | - | - | - | - |
Interest Expense |
656 K | -946 K | 2 M | -1.49 M | -366 K | -100 K | -180 K | -76 K | 551 K | -429 K | -98 K | 226 K | - | - |
EBITDA |
16.3 M | 11.7 M | 11.7 M | 6.48 M | 6.56 M | -356 M | -243 M | -150 M | -71 M | -50.7 M | -39.2 M | -20.3 M | - | - |
Operating Expenses |
- | - | - | - | - | 428 M | 292 M | 173 M | 100 M | 63 M | - | - | - | - |
General and Administrative Expenses |
359 M | 295 M | 237 M | 195 M | 158 M | 96.4 M | 47.9 M | 28 M | 19.2 M | 14.5 M | 7.89 M | 5.07 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
64.1 M | 63.7 M | 63.4 M | 62.9 M | 61.6 M | 61.1 M | 60.7 M | 60.5 M | 60.1 M | 60 M | 59.8 M | 59.6 M | 59.3 M | 59.1 M | 58.6 M | 58.4 M | 58 M | 57.8 M | 55.2 M | 54.2 M | 52.7 M | 49.3 M | 48.9 M | 48.8 M | 44.1 M | 44 M | 43.9 M | 43.9 M | 43.7 M | 43.6 M | 39.1 M | 38.8 M | 33.2 M | 33.1 M | 27.3 M | 27.2 M | 27.1 M | 27.1 M | 26.8 M | 17.1 M | 1.68 M | 1.63 M | 1.45 M | 1.37 M | 1.28 M | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
496 K | - | -56.3 M | -50 M | 89.1 M | - | -134 M | -133 M | -130 M | - | -133 M | -160 M | -106 M | - | -117 M | -108 M | -99.7 M | - | 634 M | -123 M | -111 M | -66.3 M | -94.3 M | -99.7 M | -87.4 M | -80.3 M | -72.7 M | -27 M | -56.5 M | -49 M | -37.7 M | -33.4 M | -28 M | -21.3 M | -16.8 M | -18.9 M | -15.5 M | -15.6 M | -12.6 M | -13 M | -11.6 M | -14.5 M | -10.5 M | -8.29 M | -7.03 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
149 M | - | 128 M | 138 M | 96.1 M | - | 56.6 M | 57.6 M | 63.3 M | - | 66 M | 36.5 M | 62.7 M | - | 24.2 M | 27.3 M | 21.6 M | - | 745 M | 8.34 M | 6.17 M | 51.5 M | 9.14 M | 5.11 M | 730 K | 1.03 M | 1.1 M | 41.4 M | 954 K | 1.63 M | 8.07 M | 5.89 M | 5.84 M | 7.69 M | 6.16 M | 7.06 M | 6.86 M | 4.64 M | 3.43 M | 2.69 M | 652 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
2.8 M | - | 1.93 M | 7.59 M | 3.19 M | - | 2.78 M | 2.32 M | 3.18 M | - | 3 M | 4.89 M | 5.08 M | - | 3.79 M | 6.49 M | 102 K | - | 146 K | 127 K | 24 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
461 K | - | 587 K | -1 K | 376 K | - | -728 K | -626 K | 986 K | - | 396 K | 632 K | -453 K | - | -522 K | -373 K | -214 K | - | -192 K | -23 K | -201 K | - | -72 K | -42 K | -44 K | - | 2.8 M | 2.44 M | 2.39 M | - | 954 K | 861 K | 425 K | - | 158 K | 131 K | 61 K | - | 6 K | -405 K | -37 K | - | -94 K | 1 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
4.46 M | - | - | - | 4.81 M | - | - | - | 3.68 M | - | 4.72 M | - | 1.63 M | - | 4.82 M | 1.6 M | 1.61 M | - | 4.89 M | 3.24 M | 1.57 M | - | 3.68 M | 2.39 M | 1.18 M | - | 3.08 M | 1.91 M | 780 K | - | 1.19 M | 791 K | 398 K | - | 1.19 M | 782 K | 386 K | - | 615 K | 411 K | 209 K | - | 416 K | 273 K | 134 K | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 121 M | 107 M | 109 M | 90.8 M | 84.2 M | 76.6 M | 70.9 M | 59.9 M | 51.7 M | 46.7 M | 40.1 M | 34.2 M | 29.1 M | 23 M | 26 M | 22.3 M | 20.1 M | 15.9 M | 15.1 M | 12 M | 14.3 M | 10.3 M | 8.2 M | 6.95 M | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
95.8 M | - | 89.9 M | 89.3 M | 83.6 M | - | 70.7 M | 71.9 M | 71 M | - | 57.6 M | 58.7 M | 57.1 M | - | 49.8 M | 49.3 M | 42 M | - | 37.4 M | 42.2 M | 35.7 M | - | 25.6 M | 21.9 M | 16.6 M | - | 12 M | 12.3 M | 9.91 M | - | 7.38 M | 6.83 M | 5.68 M | - | 4.89 M | 4.69 M | 4.65 M | - | 4.22 M | 3.84 M | 2.77 M | - | 1.92 M | 1.44 M | 1.57 M | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Blueprint Medicines Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
Israel
Schweiz
Australia
Britain
